Everest Medicines Ltd. (HK:1952)
:1952
Want to see HK:1952 full AI Analyst Report?
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$29.56 - HK$77.55
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$10.91B
Enterprise ValueHK$8.44B
Total Cash (Recent Filing)HK$1.59B
Total Debt (Recent Filing)HK$708.72M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Sep 02, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding353,710,400
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$69.50Price Target Upside34.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.7
Revenue Forecast (FY)HK$3.42B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthNearly doubling revenue year-over-year signals a durable commercial ramp and strong market demand for the company’s offerings. Sustained top-line expansion improves operating leverage potential and validates product-market fit, supporting longer-term scale and reinvestment capacity if trends persist.
Healthy Gross MarginsA ~60% gross margin indicates robust product-level economics and pricing power typical of differentiated biotech assets. Durable gross margins provide a buffer against cost inflation, enable sustainable contribution to R&D and SG&A, and create room for margin expansion as fixed costs are absorbed.
Improved Cash Burn With Solid CapitalizationMaterial reduction in cash burn versus 2024 combined with a sizable equity base and low leverage suggests the company has runway to continue commercialization and development. Strong capitalization and moderate debt provide structural resilience while management executes on growth initiatives.
Bears Say
Persistent UnprofitabilityOngoing net losses mean the business has not yet converted revenue growth into sustainable earnings. Persistent unprofitability can undermine return generation for equity holders, limit retained earnings for reinvestment, and increase reliance on external capital over the medium term.
Negative Operating And Free Cash FlowContinued negative operating and free cash flow indicates the company is consuming cash as it scales. That pressure constrains strategic flexibility, raises the probability of additional financing or dilution, and limits the firm’s ability to self-fund further R&D or commercial expansion.
Negative Returns To Shareholders / Capital ConsumptionConsistent negative ROE signals the company is not generating returns on invested equity, meaning capital is being consumed rather than compounded. Over time this can erode shareholder value and force financing, increasing dilution risk or prompting strategic shifts if profitability trends do not reverse.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$29.56 and its highest was HK$77.55 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$10.91B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 105 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.137 earnings per share for the quarter, missing the consensus estimate of HK$0.114 by -HK$0.251.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Undervalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is -1.05.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,710,400 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.137 in its last earnings report, missing expectations of HK$0.114. Following the earnings report the stock price went down -4.725%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$69.50 (34.95% Upside)
HK$69.50 (34.95% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
-10.55%
Trailing 12-Months
Asset Growth
44.26%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
1952 Stock 12 Month Forecast
Average Price Target
HK$69.50
▲(34.95% Upside)
Technical Analysis
InnoCare Pharma Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---